维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Georgios Perdikakis"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation显示文摘Purpose:To report preliminary 6-month results on the use of the Preserflo Microshunt implant with and without Ologen in 50 pseudophakic eyes with moderate to advanced primary open-angle glaucoma(POAG).Methods:Fifty pseudophakic eyes underwent ab externo Preserflo Microshunt implantation.Data was gathered retrospectively and two groups were then created,group A with application of MMC 0.2 mg/ml and group B with MMC 0.2 mg/ml and Ologen collagen matrix(OCM)implantation.Absolute success was regarded as the percentage of eyes achieving:a)5≤intraocular pressure(IOP)≤13 mmHg,b)5≤IOP≤16 mmHg,and c)5≤IOP≤21 mmHg without additional medication or surgery and qualified success was regarded as the percentage of eyes achieving a)IOP≤13 mmHg,b)IOP≤16 mmHg,and c)IOP≤21 mmHg with or without medication.Evaluation was performed using a log-rank Kaplan-Meier test.A scatterplot analysis presented the treatment effect data of all eyes with a minimum of 20%IOP reduction per case.Failure was defined as requiring additional surgery,IOP greater than 21 mmHg with or without medication and failure to reach 20%IOP reduction.Results:Mean postoperative IOP was significantly lower in both groups.IOP decreased by 49.06%in group A and by 53.01%in group B at 6 months(P<0.88),respectively.Medication use was lower in both groups(Wilcoxon test,P<0.001).The absolute and qualified success rates were not statistically significant between the groups(all P>0.05).Cumulative IOP results per case were not statistically different in group A compared with group B.One revision surgery in group A(4%failure rate)and three in group B(12%failure rate)were performed.Conclusions:Both groups showed equal results in terms of cumulative and mean IOP reduction,medication reduction as well as in absolute and qualified success rates.No significant difference was found in any parameters tested between Preserflo Microshunt with MMC 0.2 mg/ml and with or without OCM implantation at 6 months.Long-term follow-up is required to further evaluate this data.	Iraklis Vastardis Sofia Fili Georgios Perdikakis Kalliopi Kontopoulou Miltos Balidis Zisis Gatzioufas Markus Kohlhaas	2021	Eye and Vision2021，8，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费